Race against time: new drug combo aims to slash deaths from devastating brain infection
NCT ID NCT05590455
Summary
This study is testing if adding a drug called adalimumab to the standard treatment can help more people survive a severe brain infection called tuberculosis meningitis when they also have HIV. It will involve 130 adults in Brazil, Mozambique, and Zambia who will receive either the standard treatment alone or the standard treatment plus adalimumab injections. The main goal is to see if this addition lowers the number of deaths within three months and is safe for patients.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV I INFECTION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Adult Infectious Diseases Centre, University Teaching Hospital
NOT_YET_RECRUITINGLusaka, Zambia
Contact Email: •••••@•••••
Contact
Contact Email: •••••@•••••
-
Instituto Nacional de Saude
NOT_YET_RECRUITINGMaputo, Mozambique
Contact
Contact Email: •••••@•••••
-
Laboratory of clinical research on STD/AIDS - IPEC/FIOCRUZ
RECRUITINGRio de Janeiro, 21040-900, Brazil
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.